Blitzkrieg in psoriasis therapy: experts discussed the choice of the first biological drug

1. Langley R.G., Elewski B.E., Lebwohl M., Reich K., Griffiths C.E., Papp K. et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi: 10.1056/NEJMoa1314258.

2. Blauvelt A., Gooderham M., Iversen L., Ball S., Zhang L., Agada N.O., Reich K. Efficacy and safety of ixekizumab for the treatment of moderateto- severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017;77(5):855–862. doi: 10.1016/j.jaad.2017.06.153.

3. Al-Salama Z.T., Scott L.J. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis. Am J Clin Dermatol. 2018;19(6):907–918. doi: 10.1007/ s40257-018-0406-1.

4. Machado Á., Torres T. Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. Psoriasis (Auckl). 2018;8:83–92. doi: 10.2147/PTT.S165943.

5. Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684. doi: 10.1016/S0140-6736(08)60726-6.

6. Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S. et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606. doi: 10.1016/j. jaad.2006.05.027.

7. Lila A.M., Dreval R.О., Shipitsyn V.V. Assessment of organization of medical care and drug provision for patients with rheumatic diseases, and the socioeconomic burden of these diseases in the Russian Federation. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(3):112–119. (In Russ.) doi: 10.14412/1996-7012-2018-3-112-119

8. Gossec L., Baraliakos X., Kerschbaumer A., de Wit M., McInnes I., Dougados M. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712. doi: 10.1136/annrheumdis-2020-217159.